Skip to main content

Epigenetics in acute myeloid leukemia

This poster describes complex epigenetic mechanisms implicated in acute myeloid leukemia (AML), highlighting key targets and our broad range of proteomic tools against these targets, from recombinant

Show more
Last edited Thu 13 Oct 2022

Acute myeloid leukemia (AML) is the most common type of leukemia in adults, characterized by uncontrolled proliferation of abnormal myeloid progenitor cells. Epigenetic alterations, such as DNA methylation or histone modifications, are likely to play a critical role in the initiation and progression of AML. Several studies have found that 70% of recurring mutations in patients with AML occur in gene expression regulators, such as epigenetic proteins, transcription factors, and splicing machinery components1-4. Furthermore, several epigenetics therapies, including DNA hypomethylating agents, have been approved by regulatory authorities worldwide or are now undergoing early-phase clinical trials5.

Epigenetics in AML poster


What to expect

To help you study epigenetic mechanisms in AML, the poster covers all key established and promising epigenetics targets in acute myeloid leukemia, including:

Once you’ve downloaded the poster, click on the highlighted epigenetic targets to access the range of corresponding products.